Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1992
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party
G Read, S P Stenning, M H Cullen, et al.
Hematological Oncology
|
December 1, 1996
A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group
G M Smith, J A Child, M H Cullen, et al.
British Journal of Cancer
|
November 1, 1989
The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial
M E O'Brien, M H Cullen, C Woodroffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 18, 2009
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)
W S Owadally, M R Sydes, J A Radford, et al.
British Journal of Cancer
|
July 7, 2005
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial
G M Mead, M H Cullen, R Huddart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1994
ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group
M H Cullen, N S Stuart, C Woodroffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2008
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
M H Cullen, P Zatloukal, S Sörenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1999
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia
J M Foran, D Oscier, J Orchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report
M H Cullen, S P Stenning, M C Parkinson, et al.
British Journal of Cancer
|
May 18, 2001
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial
B W Hancock, W M Gregory, M H Cullen, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1992
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party
G Read, S P Stenning, M H Cullen, et al.
Hematological Oncology
|
December 1, 1996
A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group
G M Smith, J A Child, M H Cullen, et al.
British Journal of Cancer
|
November 1, 1989
The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial
M E O'Brien, M H Cullen, C Woodroffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 18, 2009
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)
W S Owadally, M R Sydes, J A Radford, et al.
British Journal of Cancer
|
July 7, 2005
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial
G M Mead, M H Cullen, R Huddart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1994
ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group
M H Cullen, N S Stuart, C Woodroffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2008
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
M H Cullen, P Zatloukal, S Sörenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1999
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia
J M Foran, D Oscier, J Orchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1996
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report
M H Cullen, S P Stenning, M C Parkinson, et al.
British Journal of Cancer
|
May 18, 2001
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial
B W Hancock, W M Gregory, M H Cullen, et al.
Page
of 9